Search Results - "Groover, Anna"

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study by Sullivan, Ryan J, Infante, Jeffrey R, Janku, Filip, Wong, Deborah Jean Lee, Sosman, Jeffrey A, Keedy, Vicki, Patel, Manish R, Shapiro, Geoffrey I, Mier, James W, Tolcher, Anthony W, Wang-Gillam, Andrea, Sznol, Mario, Flaherty, Keith, Buchbinder, Elizabeth, Carvajal, Richard D, Varghese, Anna M, Lacouture, Mario E, Ribas, Antoni, Patel, Sapna P, DeCrescenzo, Gary A, Emery, Caroline M, Groover, Anna L, Saha, Saurabh, Varterasian, Mary, Welsch, Dean J, Hyman, David M, Li, Bob T

“…Ulixertinib (BVD-523) is an ERK1/2 kinase inhibitor with potent preclinical activity in BRAF- and RAS-mutant cell lines. In this multicenter phase I trial…”
Get more information

Exercise-mediated improvements in painful neuropathy associated with prediabetes in mice by Groover, Anna L., Ryals, Janelle M., Guilford, Brianne L., Wilson, Natalie M., Christianson, Julie A., Wright, Douglas E.

“…Exercise reverses mechanical and visceral hyperalgesia in a prediabetic mouse model. Hyperalgesia is associated with increased nerve growth factor in the…”
Get full text

Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors by Dankner, Matthew, Wang, Yifan, Fazelzad, Rouhi, Johnson, Benny, Nebhan, Caroline A, Dagogo-Jack, Ibiayi, Myall, Nathaniel J, Richtig, Georg, Bracht, Jillian W P, Gerlinger, Marco, Shinozaki, Eiji, Yoshino, Takayuki, Kotani, Daisuke, Fangusaro, Jason R, Gautschi, Oliver, Mazieres, Julien, Sosman, Jeffrey A, Kopetz, Scott, Subbiah, Vivek, Davies, Michael A, Groover, Anna L, Sullivan, Ryan J, Flaherty, Keith T, Johnson, Douglas B, Benedetti, Andrea, Cescon, David W, Spreafico, Anna, Zogopoulos, George, Rose, April A N

“…Non-V600 mutations comprise approximately 35% of all BRAF mutations in cancer. Many of these mutations have been identified as oncogenic drivers and can be…”
Get more information

Peripheral nervous system insulin resistance in ob/ob mice by Grote, Caleb W, Groover, Anna L, Ryals, Janelle M, Geiger, Paige C, Feldman, Eva L, Wright, Douglas E

“…A reduction in peripheral nervous system (PNS) insulin signaling is a proposed mechanism that may contribute to sensory neuron dysfunction and diabetic…”
Get full text

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib) by Germann, Ursula A, Furey, Brinley F, Markland, William, Hoover, Russell R, Aronov, Alex M, Roix, Jeffrey J, Hale, Michael, Boucher, Diane M, Sorrell, David A, Martinez-Botella, Gabriel, Fitzgibbon, Matthew, Shapiro, Paul, Wick, Michael J, Samadani, Ramin, Meshaw, Kathryn, Groover, Anna, DeCrescenzo, Gary, Namchuk, Mark, Emery, Caroline M, Saha, Saurabh, Welsch, Dean J

“…Aberrant activation of signaling through the RAS-RAF-MEK-ERK (MAPK) pathway is implicated in numerous cancers, making it an attractive therapeutic target…”
Get full text

A phase 2 basket trial of ulixertinib (BVD-523) in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies harboring MAPK pathway mutations (BVD-523-HCQ) by Ko, Andrew H., Zalupski, Mark, Al-Rajabi, Raed Moh'd Taiseer, Matin, Khalid, Cohen, Deirdre Jill, Krishnamurthi, Smitha S., Kreider, Brent, Box, Jessica A., Emery, Caroline, Teresk, Martin, Varterasian, Mary Laura, Lee, Martin, Groover, Anna, Knoerzer, Deb, Shroff, Rachna T.

“…TPS4174 Background: RAS-induced signaling through the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway plays an…”
Get full text

Abstract 2693: Combining ulixertinib (ERK1/2 Inhibitor) with EGFR and BRAF inhibition yields significant efficacy in preclinical BRAF V600E mutant colorectal cancer models by Knoerzer, Deborah, Reddy, Anupama, Box, Jessica A., Groover, Anna, Kreider, Brent, Teresk, Martin, Emery, Caroline M.

“…Abstract The BRAFV600E mutation occurs in approximately 7% of colorectal cancer (CRC). BRAF plus EGFR inhibition (encorafenib with cetuximab) is an FDA…”
Get full text

Abstract 2692: The combination of ulixertinib (ERK1/2 Inhibitor) and KRASG12C inhibition demonstrates significant efficacy in preclinical models by Knoerzer, Deborah, Reddy, Anupama, Box, Jessica A., Groover, Anna, Kreider, Brent, Teresk, Martin, Emery, Caroline M.

“…Abstract Ulixertinib (BVD-523) is a first-in-class and best-in-class small molecule inhibitor of ERK1/2 currently being investigated in several oncology…”
Get full text

A two-part, phase II, multi-center study of the ERK inhibitor ulixertinib (BVD-523) for patients with advanced malignancies harboring MEK or atypical BRAF alterations (BVD-523-ABC) by Burkard, Mark E., McKean, Meredith, Rodon Ahnert, Jordi, Mettu, Niharika B., Jones, Jeremy Clifton, Misleh, Jamal Ghazi, Ma, Wen Wee, Lim, Kian-Huat, Chiorean, E. Gabriela, Pishvaian, Michael J., Gadgeel, Shirish M., McKean, Heidi Ann, Kreider, Brent, Knoerzer, Deb, Groover, Anna, Varterasian, Mary Laura, Box, Jessica A., Emery, Caroline, Sullivan, Ryan J.

“…TPS3172 Background: Ulixertinib (BVD-523) is a small molecule inhibitor of extracellular signal-regulated kinases 1/2 (ERK1/2) in development as a novel…”
Get full text

Exercise-Mediated Improvements in Painful Neuropathy Associated with Pre-Diabetes in Mice by Groover, Anna L., Ryals, Janelle M., Guilford, Brianne L., Wilson, Natalie M., Christianson, Julie A., Wright, Doug E.

“…Recent research suggests that exercise can be effective in reducing pain in animals and humans with neuropathic pain. To investigate mechanisms in which…”
Get full text

Voluntary exercise and neurotrophin signaling affect the development and presentation of painful neuropathy by Groover, Anna Lois

“…Diabetic neuropathy (DN) is the most common and debilitating complication of type 1 and type 2 diabetes with approximately half of all patients developing…”
Get full text

Voluntary exercise and neurotrophin signaling affect the development and presentation of painful neuropathy by Groover, Anna Lois

“…Diabetic neuropathy (DN) is the most common and debilitating complication of type 1 and type 2 diabetes with approximately half of all patients developing…”
Get full text